LY518674

LY518674 is a potent, selective PPARα antagonist, with an EC50 of 42 nM for human PPARα. LY518674 reduces triglycerides in and increased HDL-C and is used for the treatment of atherosclerosis.


Cat. No.: EX-A5645	Purity: >98%

	Chemical structure of LY518674

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
5mg	500	In-stock
10mg	750	In-stock
25mg	1150	In-stock
50mg	1750	In-stock
100mg	2650	In-stock

Send PO to E-mail:[email protected]; or Fax:+86 020 81619670

Discount Request


CAS No.	425671-29-0
Purity	>98%
Formula	C23H27N3O4
Mol Weight	409.4782
Color	Light yellow to yellow
State	solid powder
Solubility	Soluble in DMSO 250 mg/mL
Shelf Life	>2 years if stored properly
Storage	Powder -20℃ 2 years; In solvent -20℃ 1 month;
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Bravo Y, et al. Identification of the first potent, selective and bioavailable PPARα antagonist. Bioorg Med Chem Lett. 2014 May 15;24(10):2267-72. [2]. Nissen SE, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA. 2007 Mar 28;297(12):1362-73. [3]. Khera AV, et al. Potent peroxisome proliferator-activated receptor-α agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. Eur Heart J. 2015 Nov 14;36(43):3020-2.
CoA	CoA of LY518674


		Search